AR and prostate carcinoma: KDM3A influences the regulation of DNA damage response genes and enhances the chromatin recruitment of c‐Myc in prostate cancer through H3K9me3 demethylation.[10b] Furthermore, targeting KDM3A has the potential to sensitize prostate cancer cells to treatment by inhibiting androgen receptor activity.